{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Platinum-Resistant+Lung+Small+Cell+Carcinoma",
    "query": {
      "condition": "Platinum-Resistant Lung Small Cell Carcinoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 35,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Platinum-Resistant+Lung+Small+Cell+Carcinoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T06:48:54.753Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04607954",
      "title": "Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Platinum-Resistant Lung Small Cell Carcinoma",
        "Platinum-Sensitive Lung Small Cell Carcinoma",
        "Recurrent Extensive Stage Lung Small Cell Carcinoma",
        "Refractory Extensive Stage Lung Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lurbinectedin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2020-12-04",
      "completion_date": "2031-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-05-22T06:48:54.753Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04607954"
    },
    {
      "nct_id": "NCT02489903",
      "title": "RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Carcinoma",
        "Carcinoma, Non-Small-Cell Lung",
        "Neuroendocrine Tumors",
        "Ovarian Epithelial Cancer"
      ],
      "interventions": [
        {
          "name": "RRx-001",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        },
        {
          "name": "Doxil",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Taxane",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EpicentRx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 139,
      "start_date": "2015-06",
      "completion_date": "2021-12-06",
      "has_results": true,
      "last_update_posted_date": "2025-03-17",
      "last_synced_at": "2026-05-22T06:48:54.753Z",
      "location_count": 10,
      "location_summary": "Palo Alto, California • West Haven, Connecticut • South Bend, Indiana + 7 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "West Haven",
          "state": "Connecticut"
        },
        {
          "city": "South Bend",
          "state": "Indiana"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02489903"
    },
    {
      "nct_id": "NCT06303505",
      "title": "FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "TUB-040",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tubulis GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2024-06-12",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-05-22T06:48:54.753Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • New York, New York • Cincinnati, Ohio + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06303505"
    },
    {
      "nct_id": "NCT06463665",
      "title": "Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Non-squamous Non-small-cell Lung Cancer",
        "Advanced Squamous Non-Small Cell Lung Carcinoma",
        "Metastatic Non-squamous Non Small Cell Lung Cancer",
        "Metastatic Squamous Non-Small Cell Lung Carcinoma",
        "Non-small Cell Lung Cancer",
        "Non-small Cell Lung Cancer Stage III",
        "Non-small Cell Lung Cancer Stage IV",
        "Non-small Cell Lung Cancer Recurrent"
      ],
      "interventions": [
        {
          "name": "Olvimulogene nanivacirepvec",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Platinum chemotherapy: carboplatin or cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC",
          "type": "DRUG"
        },
        {
          "name": "Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genelux Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 142,
      "start_date": "2024-09-26",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2025-09-26",
      "last_synced_at": "2026-05-22T06:48:54.753Z",
      "location_count": 16,
      "location_summary": "Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 12 more",
      "locations": [
        {
          "city": "Bullhead City",
          "state": "Arizona"
        },
        {
          "city": "Clermont",
          "state": "Florida"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06463665"
    },
    {
      "nct_id": "NCT03944772",
      "title": "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Savolitinib",
          "type": "DRUG"
        },
        {
          "name": "Gefitinib",
          "type": "DRUG"
        },
        {
          "name": "Necitumumab",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Alectinib",
          "type": "DRUG"
        },
        {
          "name": "Selpercatinib",
          "type": "DRUG"
        },
        {
          "name": "Selumetinib",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Datopotamab deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 247,
      "start_date": "2019-06-25",
      "completion_date": "2025-05-06",
      "has_results": false,
      "last_update_posted_date": "2025-01-30",
      "last_synced_at": "2026-05-22T06:48:54.753Z",
      "location_count": 16,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 11 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03944772"
    },
    {
      "nct_id": "NCT04244552",
      "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Ovarian Cancer",
        "Non-Small Cell Lung Cancer",
        "Acral Lentiginous Melanoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "Esophageal Squamous Cell Carcinoma",
        "Urothelial Carcinoma",
        "DMMR Colorectal Cancer",
        "MSI-H Colorectal Cancer",
        "Melanoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Epithelial Ovarian Cancer",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ATRC-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegylated liposomal doxorubicin (PLD)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Atreca, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2020-02-11",
      "completion_date": "2023-11-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-05-22T06:48:54.753Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04244552"
    },
    {
      "nct_id": "NCT01363947",
      "title": "Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer, Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "DNIB0600A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2011-06-14",
      "completion_date": "2016-06-03",
      "has_results": false,
      "last_update_posted_date": "2017-06-07",
      "last_synced_at": "2026-05-22T06:48:54.753Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01363947"
    },
    {
      "nct_id": "NCT06242470",
      "title": "A Study of MGC026 in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced Cancer",
        "Metastatic Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Non Small Cell Lung Cancer",
        "Small-cell Lung Cancer",
        "Bladder Cancer",
        "Sarcoma",
        "Endometrial Cancer",
        "Melanoma",
        "Castration Resistant Prostatic Cancer",
        "Cervical Cancer",
        "Colorectal Cancer",
        "Gastric Cancer",
        "Gastro-esophageal Cancer",
        "Pancreas Cancer",
        "Clear Cell Renal Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "Platinum-resistant Ovarian Cancer",
        "Breast Cancer",
        "Ovarian Cancer",
        "Esophageal Squamous Cell Cancer (SCC)"
      ],
      "interventions": [
        {
          "name": "MGC026 Dose Escalation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MGC026 Dose for Expansion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2024-03-06",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-05-22T06:48:54.753Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Grand Rapids, Michigan • Lake Success, New York + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06242470"
    },
    {
      "nct_id": "NCT02468661",
      "title": "A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "INC280 single agent",
          "type": "DRUG"
        },
        {
          "name": "erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2015-09-23",
      "completion_date": "2018-12-05",
      "has_results": false,
      "last_update_posted_date": "2020-02-24",
      "last_synced_at": "2026-05-22T06:48:54.753Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Orange, California • Detroit, Michigan + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02468661"
    },
    {
      "nct_id": "NCT04504916",
      "title": "A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple-negative Breast Cancer",
        "Non-squamous Non-small-cell Lung Cancer",
        "NSCLC",
        "Estrogen-receptor-positive Breast Cancer",
        "Progesterone-receptor-positive Breast Cancer",
        "Estrogen-receptor-negative Breast Cancer",
        "ER-negative Breast Cancer",
        "Progesterone-receptor Negative Breast Cancer",
        "PR-negative Breast Cancer",
        "HER2-negative Breast Cancer",
        "ER-positive Breast Cancer",
        "PR-positive Breast Cancer",
        "Platinum-resistant Ovarian Cancer",
        "Gastric Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Zilovertamab vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2020-10-07",
      "completion_date": "2023-06-12",
      "has_results": true,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-05-22T06:48:54.753Z",
      "location_count": 8,
      "location_summary": "Hollywood, Florida • Orlando, Florida • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04504916"
    }
  ]
}